Indications for: Phendimetrazine Tartrate
Short-term adjunct in managing exogenous obesity.
35mg 2 or 3 times daily, 1 hour before meals; may reduce to 17.5mg/dose. Max 210mg/day in 3 evenly divided doses.
<12yrs: not recommended.
Phendimetrazine Tartrate Contraindications:
Advanced arteriosclerosis. Cardiovascular disease. Moderate or severe hypertension. Hyperthyroidism. Glaucoma. Highly nervous or agitated states. Drug or alcohol abuse. Concomitant CNS stimulants. During or within 14 days of MAOIs (see Interactions).
Phendimetrazine Tartrate Warnings/Precautions:
Discontinue after a few weeks as tolerance to anorectic effect occurs. Avoid abrupt cessation after prolonged high doses. Mild hypertension. Abuse and dependence potential. Diabetes. Reevaluate after drug-free interval. Prescribe minimal supply to avoid overdose. Pregnancy.
Phendimetrazine Tartrate Classification:
Phendimetrazine Tartrate Interactions:
Hypertensive crisis with MAOIs. May antagonize guanethidine. CNS effects with alcohol, other CNS drugs.
Palpitation, tachycardia, hypertension, CNS overstimulation, dry mouth, GI disturbances, urinary frequency, changes in libido.
Formerly known under the brand name Bontril PDM.
The major route of elimination is via the kidneys where most of the drug and metabolites are excreted. Some of the drug is metabolized to phenmetrazine and also phendimetrazine-N-oxide.
The average half-life of elimination is about 3.7 hours for both the extended-release and immediate release forms.